Asset is a fully integrated, uHTS system that can process a plate every 30 seconds, with one operator using any assay technology.   Asset offers a unique combination of flexibility, assay quality (Z') and throughput.   Asset is operational at major pharmaceutical sites, including GlaxoSmithKline and AstraZeneca, routinely screening large compound libraries against a wide range of assay types.     Batch sizes in excess of 400 plates with lids (96, 384 or 1536 well) using PlateSafes Reagent addition using temperature controlled reservoirs with optional gassing and agitation Tip washing and drying, in parallel with pipetting Tissue culture quality incubation with CO2 and humidity control Finely controlled plate washing for cell-based, coated-well and ELISA procedures Signal detection using multiple readers of user’s choice Complete sample tracking giving full audit trail Unlimited multi-stream transfers between compound, cell and assay plates within an assay   Processing capacity to handle all likely workloads - screens 250,000 compounds in 8 hours, to meet peak demands and complete high priority screens quickly Consistent and reproducible results for even complex multi-stream uHTS assays - using Asset’s proprietary plate indexing system Flexibility to assemble and measure the full range of assays – ELISAs, as well as sensitive cell-based assays Rapid and simple changeover between different assays Reliable, unattended operation enables extended-hours runs Choice of user-specified assay technology and plate readers   Asset’s unique processing style delivers optimised Z’ values at uHTS throughputs, regardless of assay format. This enables screening groups to deliver enhanced service to their clients in therapeutic areas.   Ultra high throughput screening (uHTS)   For more information on Asset:   Get more detail on the systems' Key Applications   Discuss your requirements with Ian Ransome, Sales Director << Back to the range of TAP Sample Management & Screening Systems Back to top   print page